2025年2月20日 · Background: In the EMPA-KIDNEY trial, empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic …

2022年11月4日 · Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease …

Empagliflozin is used together with diet and exercise to lower blood sugar levels in adults and children at least 10 years old with type 2 diabetes. Empagliflozin is also used to lower the risk …

2024年11月11日 · empa-kidney是一项国际多中心、随机、双盲、安慰剂对照的临床研究，2022年主试验和2023年其他亚组分析均验证了钠-葡萄糖共转运蛋白2 抑制剂（sglt2i）恩格列净 …

In this exploratory analysis of the EMPA-REG OUTCOME trial, we report the short-term and long-term effects of empagliflozin on albuminuria in patients with type 2 diabetes and established …

In this exploratory analysis of the EMPA-REG OUTCOME trial, we report the short-term and long-term effects of empagliflozin on albuminuria in patients with type 2 diabetes and established …

2023年1月12日 · Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease …

2023年8月23日 · More recently, the EMPA-KIDNEY trial showed that among a wide range of patients with CKD (eGFR of 20–90 mL/min/1.73 m 2), empagliflozin therapy led to a lower risk …

2024年12月18日 · Sodium–glucose co-transporter 2 inhibitors have revolutionized the management of chronic kidney disease. However, long-term data regarding their use are …

2024年10月25日 · In the EMPA-KIDNEY trial, empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who …